At Celldex, we are committed to developing safe and effective therapies for patients with devastating diseases for which available treatments are inadequate.

We understand the importance of bringing these therapies to the broadest group of patients as quickly as possible. By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease.

Clinical studies collect the information necessary to understand the safety and efficacy of the potential therapy allowing for regulatory review and potential approval.

To learn more about our ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov or email .

Visit here to learn more about our Compassionate Use or Expanded Access Program.

Candidate Phase Identifier Indication
CDX-0159 Phase 1 External link opents in a new window NCT04538794 Chronic Spontaneous Urticaria
CDX-0159 Phase 1 External link opents in a new window NCT04944862 Prurigo Nodularis
CDX-0159 Phase 1 External link opents in a new window NCT04548869 Cold Contact Urticaria, Symptomatic Dermographism, Cholinergic Urticaria
CDX-1140 Phase 1 External link opents in a new window NCT03329950 Cancer – multiple tumor types
CDX-527 Phase 1 External link opents in a new window NCT04440943 Cancer – multiple tumor types